Taxus Cardium Pharmaceuticals Group Inc (CRXM)

[docj]

About the company
Gene Biotherapeutics Inc., formerly Taxus Cardium Pharmaceuticals Group Inc., is engaged in managing a medical technologies portfolio of equity-based and potential royalty-driven investments. The Company's portfolio includes Angionetics, Inc. (Angionetics); Activation Therapeutics, Inc. (Activation Therapeutics); LifeAgain Insurance Solutions, Inc. (LifeAgain), and a minority investment in Healthy Brands Collective. Angionetics is its subsidiary focused on late-stage clinical development and commercialization of Generx, which is an angiogenic gene therapy product candidate designed for medical revascularization for treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Activation Therapeutics is its subsidiary focused on development and commercialization of Excellagen technology platform, which is a flowable dermal matrix for wound care that has application as a delivery platform for small molecule drugs, proteins and biologics.